{
    "SPADE_UN_21421": {
        "Sequence Information": {
            "Peptide Name": "Cyclic Tachyplesin-1",
            "Sequence": "KWCFRVCYRGICYRRCRG",
            "Sequence Length": 18,
            "Biological Activity": [
                "Anti-Gram+",
                "Anti-Gram-",
                "Anticancer",
                "Anti-Mammalian Cell"
            ],
            "Binding Target": "1. Lipid Bilayer",
            "Source": "",
            "Gene": "",
            "PDB ID": "6PIN",
            "UniProt Entry": [
                {
                    "uniprotId": "P69136",
                    "uniprotUrl": "http://www.uniprot.org/uniprot/P69136",
                    "description": "The amino acid sequence of the current peptide coincides with the amino acid sequence of the UniProt entry."
                }
            ],
            "Literature": [
                {
                    "Title": "Characterization of Tachyplesin Peptides and Their Cyclized Analogues to Improve Antimicrobial and Anticancer Properties.",
                    "Pubmed ID": "31455019",
                    "Reference": "Int J Mol Sci. 2019;20:",
                    "Author": "Vernen F, Harvey PJ, Dias SA, Veiga AS, Huang YH, Craik DJ, Lawrence N, Troeira Henriques S",
                    "URL": "http://www.ncbi.nlm.nih.gov/pubmed/31455019"
                },
                {
                    "Title": "Cyclic Analogues of Horseshoe Crab Peptide Tachyplesin I with Anticancer and Cell Penetrating Properties.",
                    "Pubmed ID": "31714739",
                    "Reference": "ACS Chem Biol. 2019;14:2895-2908",
                    "Author": "Vernen F, Craik DJ, Lawrence N, Troeira Henriques S",
                    "URL": "http://www.ncbi.nlm.nih.gov/pubmed/31714739"
                }
            ],
            "Mass": 2325.81,
            "PI": 9.93,
            "Net Charge": 6,
            "Hydrophobicity": -0.51,
            "Frequent Amino Acids": "RCG",
            "Absent Amino Acids": "ADEHLMNOPQSTU",
            "Basic Residues": 6,
            "Acidic Residues": 0,
            "Hydrophobic Residues": 7,
            "Polar Residues": 11,
            "Positive Residues": 6,
            "Negative Residues": 0,
            "SPADE ID": "SPADE_UN_21421",
            "Similar Sequences": [
                {
                    "SPADE_ID": "SPADE_N_02532",
                    "Similarity": 1.0,
                    "Sequence": "KWCFRVCYRGICYRRCR"
                },
                {
                    "SPADE_ID": "SPADE_N_07952",
                    "Similarity": 1.0,
                    "Sequence": "MKKLVIALCLMMVLAVMVEEAEAKWCFRVCYRGICYRRCRGKRNEVRQYRDRGYDVRAIPEETFFTRQDEDEDDDEE"
                },
                {
                    "SPADE_ID": "SPADE_N_15019",
                    "Similarity": 1.0,
                    "Sequence": "KWCFRVCYRGICYRRCRGK"
                }
            ],
            "Hemolytic Activity": "Human erythrocytes:50% Hemolysis=106.9±21.0 µM,Human keratinocytes HaCat:50% Cell death=7.9±0.5 µM",
            "Target Organism": "Escherichia coli ATCC 25922(MIC=1µM),Escherichia coli DC2(MIC=4µM),Staphylococcus aureus ATCC 25923(MIC=2-8µM),Staphylococcus aureus ATCC 6538(MIC=8µM),Human skin melanoma MM96L(50% Cell death=1.3±0.1µM),Human malignant melanoma HT-144(50% Cell death=1.4±0.1µM),Human metastatic melanoma WM164(50% Cell death=2.7±0.1µM),Human cervical carcinoma HeLa(50% Cell death=6.7±0.6µM),Human breast adenocarcinoma MDA-MB-435S(50% Cell death=2.7±0.3µM),Human myelogenous leukemia K562(50% Cell death=2.0±0.1µM),Human breast adenocarcinoma MCF-7(50% Cell death=6.4±0.6µM)"
        }
    }
}